ライフサイエンスコーパス: postprocedure

1 ng/mL increase in cTnT measured at 18-24 hrs postprocedure.

2 re in serum creatinine level within 96 hours postprocedure.

3 ed for HFH was highest in the first 3 months postprocedure.

4 ine; and 11.9% developed atrial fibrillation postprocedure.

5 36 hours or less postprocedure, and 30 days postprocedure.

6 ovement in symptoms of NAO through 12 months postprocedure.

7 tients (23%) had no intensive care unit stay postprocedure.

8 all thrombus fragment recovered from the CPD postprocedure.

9 ntative sample and followed up for 12 months postprocedure.

10 sence of more than mild aortic regurgitation postprocedure.

11 emodynamic indices obtained preprocedure and postprocedure.

12 plates and in air samples taken 6 to 10 min postprocedure.

13 TAVR did not improve their exercise capacity postprocedure.

14 days, and 4.9% (5/102) between 8 and 30 days postprocedure.

15 portant clinical outcomes during the 30 days postprocedure.

16 high risk of major adverse limb events early postprocedure.

17 6.0 [5.0-6.0], P<0.001), and up to 48 hours postprocedure.

18 14 U.S. sites and followed up for 12 months postprocedure.

19 target vessel revascularization) at 9 months postprocedure.

20 se arch diameter to be similar, 0.91 0.09 to postprocedure 0.86 0.14.

21 Seventeen children died in-hospital postprocedure (15%).

22 ected, including preprocedure (baseline) and postprocedure (24 hours, 48 hours, 7 days, and 28 days)

23 sive care unit stay (1 day), hospitalization postprocedure (4.5 days), and blood loss (1100 mL) all d

24 Postprocedure, 59% of children were weaned completely fr

25 9+/-29.2% [P<0.0001]), but underestimated it postprocedure (6.9+/-11.3% versus 28.1+/-33.4% [P<0.0001

26 use was reduced at 6 weeks (preprocedure vs postprocedure, 91.3 g +/- 121 vs 64.6 g +/- 124, respect

27 ated with AAM titration and the variation in postprocedure AAM management after CTO PCI across hospit

28 udies based on agent and preprocedure versus postprocedure administration.

29 Moderate pneumothorax was defined as a postprocedure air rim of 2 cm or greater.

30 We investigated 3D intravascular ultrasound (postprocedure and 6 to 9 months) in 971 patients (267 wi

31 sound data >/=10 mm distal to the stent both postprocedure and at 9 months follow-up.

32 h known procedure date who survived 24 hours postprocedure and did not have inflammatory bowel diseas

33 serial sera acquired over the first 10 days postprocedure and examined for correlation with achievem

34 Immediately postprocedure and then 1 mo later, patients rated their

35 were measured at 3, 6, 12, 24, and 36 months postprocedure and used to derive TTR.

36 outcome was the composite of acute (<7 days postprocedure) and chronic (>7 days) major adverse event

37 mes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events

38 cedure, at index-procedure, 36 hours or less postprocedure, and 30 days postprocedure.

39 ant changes in testosterone preprocedure and postprocedure, and all demonstrated significant increase

40 d by cardiac magnetic resonance at baseline, postprocedure, and at 7- or 30-day follow-up.

41 rd to percent obliteration of an aneurysm on postprocedure angiogram, the duration and intensity of a

42 on tomography (PET) at baseline and 6 months postprocedure assessed enzyme activity; standard assessm

43 toring, (d) intraprocedural control, and (e) postprocedure assessment.

44 on of patients with Troponin T levels >3xULN postprocedure (at 6 or 18-24 hours), where ULN stands fo

45 Postprocedure bleeding occurred in 3.5% of patients in t

46 Postprocedure bleeding occurred in only 1 patient (SOC g

47 in would be associated with less in-hospital postprocedure bleeding than UFH but similar rates of in-

48 n in patients with significant coagulopathy, postprocedure bleeding was rare, indicating that TEG thr

49 Subgroup analyses included postprocedure bleeding with polyp location, polyp size,

50 rmine in-hospital mortality but also predict postprocedure bleeding, acute kidney injury, and stroke

51 The primary outcome, postprocedure bleeding, was defined as a severe bleeding

52 ection of large colon polyps reduces risk of postprocedure bleeding.

53 compression), strong tumor blush, and major postprocedure blush reduction are predictors of clinical

54 Postprocedure brain magnetic resonance imaging revealed

55 The occurrence of postprocedure bursitis was recorded.

56 Efficacy end points and postprocedure cardiac enzyme were similar, but there was

57 This study sought to evaluate patterns of postprocedure care after LAAO with the Watchman device i

58 imalist periprocedure approach, standardized postprocedure care with early mobilization and reconditi

59 ration, sedation, hemostatic techniques, and postprocedure care.

60 ght common preprocedure, intraprocedure, and postprocedure catheterization laboratory practices where

61 Exploratory end points included immediate postprocedure change in mean pulmonary artery pressure a

62 eed for LT should be reassessed, informed by postprocedure changes in MELD-Na and clinical status.

63 There was no difference in the rating of postprocedure chest discomfort (median in both groups =

64 s to analyze the incidence and predictors of postprocedure chest pain (PPCP) after percutaneous coron

65 ocker therapy had lower persistent/recurrent postprocedure chest pain and lower preprocedure and post

66 Postprocedure chest pain is associated with similar shor

67 osition in the ipsilateral IJ as detected by postprocedure chest radiograph.

68 Routine postprocedure chest radiographs are considered standard

69 Data from standardized procedure notes and postprocedure chest radiographs were extracted and indiv

70 undergo diagnostic thoracentesis do not need postprocedure chest radiography.

71 s at 30 days and 6 months were stratified by postprocedure CK and CK-MB (multiple of the site's upper

72 The strongest correlate of postprocedure CK-MB elevation was the performance of dir

73 edure, early (24 hours), and late (9 months) postprocedure CMR imaging.

74 There was a significant change in WBC count postprocedure compared with baseline: in the control arm

75 .18% [95% CI, 0.15%-0.20%]; P <.001) and any postprocedure complication (3.23% [95% CI, 3.01%-3.45%]

76 VE and hepatic resection was determined with postprocedure complication rate and median hospital stay

77 achieved in all procedures without intra- or postprocedure complications because there was high vascu

78 Postprocedure complications were less frequent with BVR

79 Postprocedure complications were noted in five of 56 (9%

80 Intraprocedure and postprocedure complications were similar between the gro

81 y outcomes included revascularization, major postprocedure complications, and angina after a 3.5-year

82 In the Medicare subset analyzed for postprocedure complications, there was no difference wit

83 There were no postprocedure complications.

84 Sheath-vessel diameter ratio, postprocedure compression time, occlusive hemostasis, an

85 Immediate postprocedure computed tomography (CT) of the abdomen he

86 Postprocedure contrast enhancement was clearly identifie

87 utting the ablation zone was identified with postprocedure contrast material-enhanced computed tomogr

88 ary intervention (PCI) with an uncomplicated postprocedure course is low.

89 t in less myocardial necrosis as assessed by postprocedure creatine kinase (CK) levels.

90 ry intervention, we studied the incidence of postprocedure creatine kinase (CK)-MB elevation in patie

91 Postprocedure CT images were evaluated by two radiologis

92 Patients were followed up for 30 days postprocedure; database closure was on August 25, 2021.

93 ection (1.44 vs. 0.44, P < 0.001) but not on postprocedure day 1 (1.04 vs. 0.48, P = 0.06).

94 Compared with postprocedure day 1, every 90 days there is a decrease o

95 All patients reported relief of symptoms on postprocedure day 1.

96 anced multiphase MR imaging was performed on postprocedure days 1 and 30 and every 90 days thereafter

97 eprocedure bedside "time-out," and immediate postprocedure debriefing).

98 A postprocedure decrease in the hematocrit level of more t

99 tcomes than visual comparison using pre- and postprocedure diagnostic images following MWA of CRLM.

100 bination of different stents (p = 0.013) and postprocedure dissections (p = 0.014) and slow flow (p =

101 ues were collected at 0, 7, 14, 21, and 56 d postprocedure (dpp) for analysis by micro-computed tomog

102 was the numerical difference in new positive postprocedure DWMRI brain lesions at 2 days after TAVI i

103 , as well as a potentially decreased risk of postprocedure ectasia.

104 ization EF measured, we calculated delta-EF (postprocedure EF-preprocedure EF).

105 ociated with significantly worse outcomes in postprocedure endophthalmitis, independent of presenting

106 Postprocedure esophagogastroduodenoscopy revealed minor

107 rimary outcome measure was SSI up to 30 days postprocedure, evaluated by an assessor masked to the ra

108 Nearly 40% of patients did not restart OAC postprocedure, exposing patients to risk for stroke.

109 [83.9%] treated via femoral access), 30-day postprocedure follow-up data was assessed in all patient

110 n to evaluate changes in pain score over the postprocedure follow-up period.

111 es, OCT-guided PCI is associated with higher postprocedure fractional flow reserve than PCI guided by

112 n a transaortic constriction model [at 10 wk postprocedure, fractional shortening was 0.31 +/- 0.02 i

113 Postprocedure gadolinium-enhanced MR imaging and clinica

114 Average postprocedure ghrelin values increased by 328.9 pg/dL +/

115 A successful result, defined as a postprocedure gradient of < or =20 mm Hg, was achieved i

116 cedure chest pain and lower preprocedure and postprocedure heart rates and mean blood pressures compa

117 Routine postprocedure heparin is not recommended, even in patien

118 Nd:YAG-caps, mainly observed within 3 months postprocedure, highlighting the need for a close follow-

119 ement, there has been a temporal decrease in postprocedure hospital admission.

120 Mean postprocedure hospital stay varied from 8 days to 51 day

121 7.2%) were technically successful, with mean postprocedure hospitalization of 2 days +/- 3.

122 dependent readers visually assessed pre- and postprocedure images and semiquantitatively scored for i

123 Preliminary and postprocedure imaging is usually limited to CT for anato

124 e intention-to-treat population, at 3 months postprocedure, improvement in FEV1 from baseline was 13.

125 educed risk of PV stenosis compared with IRF postprocedure in a canine model.

126 rocedural risk factors for dying in-hospital postprocedure included intensive care unit admission (ha

127 Thirteen patients developed postprocedure infection (1.5%), 9 (2.0%) in the white pe

128 However, DSAEK may also be associated with postprocedure intraocular pressure elevation and seconda

129 Postprocedure length of stay, days (1.4+/-0.2 radial vs.

130 S was characterized as study LOS, defined as postprocedure LOS for patients who underwent a procedure

131 Postprocedure lumen and vessel were not significantly di

132 ajor predictor of restenosis being a smaller postprocedure lumen diameter.

133 Inadequate postprocedure lumen dimensions, alone or in combination

134 er PCI, principally by resulting in a larger postprocedure lumen than with angiographic guidance.

135 At postprocedure, lumen VI at the stented segment was signi

136 han 1.0 cm (range, 1.1-2.6 cm) compared with postprocedure mammogram the day of placement, three of f

137 Postprocedure mammograms demonstrated accurate placement

138 masses with a diameter of 2 cm or larger on postprocedure mammograms.

139 echnical considerations for stent placement, postprocedure management, and future research/educationa

140 ticoagulant treatment, nor did the immediate postprocedure mean intraocular pressure (P = .13).

141 , adjusting for baseline characteristics and postprocedure medications.

142 DCB had a lower postprocedure minimum lumen diameter but lower late lume

143 e vessel diameter, the PPCP group had larger postprocedure minimum lumen diameter, higher stent-to-ve

144 lity, stent thrombosis, late lumen loss, and postprocedure minimum lumen diameter.

145 tly this involves no explicit comparisons of postprocedure mortality across hospitals.

146 o identify hospitals with statistically high postprocedure mortality rates.

147 I of the prostate at 48 to 72 h, followed by postprocedure mpMRI/ultrasound targeted fusion biopsies

148 n a large region of enhancement on immediate postprocedure MR images that, over time, involutes and i

149 Postprocedure MSA and follow-up minimum lumen area (MLA)

150 edictability of long-term stent patency with postprocedure MSA.

151 scularization was determined by the residual postprocedure myocardial jeopardy index (RMJI).

152 Postprocedure, New York Heart Association symptoms impro

153 At 7 days postprocedure, no child had persistent behavioral abnorm

154 Postprocedure OCT was performed in all patients.

155 (0.3 mg/kg or 1 mg/kg) was i.v. administered postprocedure on days 0 and 5.

156 aditionally focused on processes of care and postprocedure outcomes.

157 PVL improved postprocedure (P<0.001) and was none (33.3%), mild (41.4

158 TSMB improved surgeon postprocedure pain scores in the neck, lower back, shoul

159 rine flow rates greater than 150 ml/h in the postprocedure period were significantly lower, 8/37 (21.

160 During the 30-day postprocedure period, 178 clinical events occurred in 12

161 Postprocedure platelet counts increased only slightly (m

162 ion, ventilator-associated pneumonia/events, postprocedure pneumonia, methicillin-resistant Staphyloc

163 rgical source control was performed (pre- vs postprocedure, posterior probability >0.99).

164 The predominant adverse effect was postprocedure proctalgia lasting a few days.

165 Comparative measurements from the postprocedure radiograph were made in 20 of these cases.

166 Sixteen patients had postprocedure radiographs performed.

167 ndred central venous catheter exchanges with postprocedure radiographs were evaluated in phase I.

168 years) experienced TNR for a mean of 36 days postprocedure (range, 19-54 days).

169 determined primarily by the smaller lumen at postprocedure rather than exaggerated neointima within t

170 st-POEM setting, given the increased risk of postprocedure reflux and esophagitis.

171 ith comparable efficacy, safety, and rate of postprocedure reflux between these 2 approaches.

172 pertains to treatment efficacy and risk for postprocedure reflux, remains to be determined.

173 own a graded relationship with the degree of postprocedure renal failure and the probability of in-ho

174 with atherectomy plus PTCA resulted in lower postprocedure residual stenoses than PTCA alone (16+/-15

175 Independent predictors for a postprocedure residual TR of >moderate were coaptation g

176 mediate renal denervation (n=47) and 6-month postprocedure results for crossover patients are present

177 Mean (+/-SD) baseline and postprocedure RV/LV diameter ratio, pulmonary artery sys

178 Pre- and postprocedure SCr levels were assessed.

179 Postprocedure secondary patency with multiple PFSS proce

180 stents had significantly higher incidence of postprocedure strictures (P = 0.006).

181 Among patients in ARISTOTLE, the 30-day postprocedure stroke, death, and major bleeding rates we

182 During the 30 days postprocedure, stroke or systemic embolism occurred afte

183 In the EVT group, the rate of postprocedure successful reperfusion (>=modified Treatme

184 BEST PRACTICE ADVICE 11: Long-term postprocedure surveillance is encouraged to monitor for

185 nts at risk of significant cognitive decline postprocedures that benefit from targeted cognitive trai

186 stimates were categorized into the following postprocedure time point groups: 1 hour or less, 1 to 24

187 there was a significant plaque increase from postprocedure to 9-month follow-up for PES (P=0.0008) bu

188 examinations were performed at baseline and postprocedure to identify stroke, disabling stroke, and

189 One-year postprocedure, TR severity significantly reduced (P < 0.

190 moral PCI 96.6%; P=0.182), or in the risk of postprocedure transfusion or mortality.

191 0.78 [95% CI, 0.67 to 0.90]; P = 0.001) and postprocedure transfusions (OR, 0.85 [CI, 0.74 to 0.96];

192 uccessful LAAO, only 12.2% received the full postprocedure treatment protocol studied in pivotal tria

193 l U.S. Food and Drug Administration-approved postprocedure treatment protocols studied in pivotal tri

194 ial appendage occlusion (LAAO) used specific postprocedure treatment protocols.

195 We assessed adherence to the full postprocedure trial protocol including standardized foll

196 imes (at 1, 4, 24 hours and at 7 and 14 days postprocedure) until no longer detectable.

197 Mean gradient across the mitral valve postprocedure was 5.7 2.8 mm Hg ( 5 mm Hg; 61.4% of pati

198 Mean gradient across the mitral valve postprocedure was 5.7+/-2.8 mm Hg (>=5 mm Hg; 61.4% of p

199 tion of the index limb at 30 days (+ 7 days) postprocedure was achieved in 99.2% (258/260) of patient

200 Average length of stay postprocedure was decreased significantly for both the M

201 eference segments, residual plaque burden at postprocedure was significantly greater in DM than in no

202 Freedom from atrial arrhythmias at 12 months postprocedure was similar compared with the primary stud

203 or behavioral abnormalities within 24 hours postprocedure was similar in both treatment groups.

204 The average postprocedure weight gain in experimental animals was si

205 with available statin data (preprocedure and postprocedure) were included.

206 phy/magnetic resonance imaging (also 6-month postprocedure) were performed.

207 hese remain well, off ERT (5, 4, and 3 years postprocedure), with gene marking in PBMC of 1%-10%, and

208 rate was 77.3% (51 participants) at 30 days postprocedure, with a median (IQR) overall survival time

209 t of performing a brief but thorough routine postprocedure wound/body cavity exploration before wound

210 The highest quartile of postprocedure XV height (>8 mm Hg) had worse event-free

211 Postprocedure XV height correlated with TR severity as d

212 During the first postprocedure year, patients' angina burden and physical